IP Library Granted Patent US 10,517,901
Granted Patent B2
US 10,517,901 · App. 15/961,720 · Granted Dec 31, 2019

Methods of lowering blood glucose levels in a mammal

Inventors: Laura Martinson (San Diego, CA); Evert Kroon (San Diego, CA); Kevin D'Amour (San Diego, CA); Emmanuel Edward Baetge (Encinitas, CA)
Assignee: ViaCyte, Inc.
A61K35/39A61K38/26A61K38/28C12N5/0676C12N5/0678A61K35/12C12N2500/38C12N2501/10C12N2501/105C12N2501/113C12N2501/115C12N2501/119C12N2501/12C12N2501/16C12N2501/33C12N2501/385C12N2501/41C12N2501/415C12N2501/42C12N2501/58C12N2501/999C12N2506/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,517,901
App. No.
15/961,720
Granted
Dec 31, 2019
Kind
B2
Abstract

Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.

Claims (13)

1. A method of lowering blood glucose levels in a human in need thereof, said method comprising the steps of:

a) transplanting a cell culture comprising, (i) human pancreatic duodenum homeobox 1 (PDX-1) positive pancreatic endoderm cells and (ii) human endocrine precursor cells that express neurogenin 3 (NEUROG3) into the human; and

b) maturing in vivo the transplanted cells of step a) into insulin secreting cells, wherein the insulin secreting cells secrete insulin in response to glucose stimulation, thereby lowering the blood glucose levels of the human.

2. The method of claim 1 , wherein the endocrine precursor cells that express NEUROG3 also express paired box gene 4 (PAX4) and NKX2 transcription factor related locus 2 (NKX2.2).

3. The method of claim 1 , wherein the insulin secreting cells express NKX6 transcription factor related locus 1 (NKX6.1).

4. The method of claim 1 , wherein the method further comprises, step c) measuring insulin secretion.

5. The method of claim 4 , wherein insulin secretion is determined by measuring C-peptide levels in blood of the human.

6. The method of claim 5 , wherein C-peptide levels are measured over time.

7. The method of claim 1 , wherein the insulin secreting cell number increases over time.

8. The method of claim 1 , wherein the insulin secreting cells form islet-like cell clusters.

9. The method of claim 1 , wherein the transplanted cells of step b) form pancreatic epithelium.

10. The method of claim 9 , wherein the pancreatic epithelium expresses NKX6.1.

11. The method of claim 9 , wherein the pancreatic epithelium expands over time.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2018
From: MARTINSON, LAURA; KROON, EVERT; D'AMOUR, KEVIN; BAETGE, EMMANUEL E.
To: CYTHERA, INC.
Reel/Frame 045637/0791 →
CHANGE OF NAME Recorded Apr 25, 2018
From: CYTHERA, INC.
To: VIACYTE, INC.
Reel/Frame 046021/0400 →
Continuity (9)
Continuation 14670249 · Mar 26, 2015
Continuation 13205511 · Aug 8, 2011
Continuation 12758734 · Apr 12, 2010
Continuation 11773944 · Jul 5, 2007
Continuation In Part 11681687 · Mar 2, 2007
Provisional Application 60852878 · Oct 18, 2006
Provisional Application 60833633 · Jul 26, 2006
Provisional Application 60778649 · Mar 2, 2006
Related Publication 20180236006A1 · Aug 23, 2018
Cited By (1)
US 12,441,985